P078

Pathogenic Mycobacteria of the complex Mycobacterium tuberculosis (MTb) are the causative agents of human Tuberculosis. Current reports after the COVID-19 pandemic continue to show that pathogenic mycobacteria constitutes a health public problem that is worsened by the increasing multidrug-resistance strains (MDR), by the co-morbidities and by the lack of long-term memory of the actual and official approved vaccine BCG. Approximately 1.7 million deaths annually and morbidity of 10.6 million. While most of the infected individuals remain not symptomatic, a percentage (5%) develop active disease.  During most of their life, only 5 % develop active disease. Molecular diagnostics based on real-time PCR, and whole genome sequencing have made significant improvements to early detection and specificity sensibility. Transcriptomics has contributed also in terms of the biomarkers of the course and progression of the disease. In previous work, we isolated M. bovis/M tuberculosis of exudate from humans and characterized the serological reactivity and genic expression profile with encouraging results. Furthermore, several studies have highlighted that cell wall lipids of pathogenic mycobacteria play a role as a factor of virulence and are recognized by the innate immune cells, resulting in effective connection with the adaptive immune system, especially those by B and T lymphocytes. Therefore, we pursue to characterize and update the status of BCG strains and utmost of pathogenic mycobacteria of the complex of Mycobacterium tuberculosis, in terms of the lipids profile using chromatographic techniques. We agree that lipids can be harnessed and targeted for the improvement of the BCG vaccine.